TACSTD2 and renal cell carcinoma: Notwithstanding that loss of mRNA expression of TACSTD2 has been described for RCC [34], to our knowledge, DNA methylation alterations of TACSTD2 and its association with clinicopathology in RCC have not been investigated so far.